More research is also needed to clearly establish the association between BRCA2 mutation and the development of early-onset and aggressive colon cancer and to inform decisions on when colon cancer screening should be initiated in patients with BRCA2 mutation if an association is found. Overall, patient awareness and adherence to screening recommendations will reduce the morbidity and mortality associated with CRC. This evidence concerns the gene BRCA2 and malignant colon neoplasm.